These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22735380)

  • 1. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.
    Quetglas JI; Dubrot J; Bezunartea J; Sanmamed MF; Hervas-Stubbs S; Smerdou C; Melero I
    Mol Ther; 2012 Sep; 20(9):1664-75. PubMed ID: 22735380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
    Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
    Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma.
    Rodriguez-Madoz JR; Liu KH; Quetglas JI; Ruiz-Guillen M; Otano I; Crettaz J; Butler SD; Bellezza CA; Dykes NL; Tennant BC; Prieto J; González-Aseguinolaza G; Smerdou C; Menne S
    J Virol; 2009 Dec; 83(23):12266-78. PubMed ID: 19740992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.
    Kwong B; Gai SA; Elkhader J; Wittrup KD; Irvine DJ
    Cancer Res; 2013 Mar; 73(5):1547-58. PubMed ID: 23436794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
    Ballesteros-Briones MC; Martisova E; Casales E; Silva-Pilipich N; Buñuales M; Galindo J; Mancheño U; Gorraiz M; Lasarte JJ; Kochan G; Escors D; Sanchez-Paulete AR; Melero I; Prieto J; Hernandez-Alcoceba R; Hervas-Stubbs S; Smerdou C
    Mol Ther; 2019 Nov; 27(11):1892-1905. PubMed ID: 31563534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12.
    Yamanaka R; Tsuchiya N; Yajima N; Honma J; Hasegawa H; Tanaka R; Ramsey J; Blaese RM; Xanthopoulos KG
    J Neurosurg; 2003 Oct; 99(4):746-53. PubMed ID: 14567611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography.
    Asselin-Paturel C; Lassau N; Guinebretière JM; Zhang J; Gay F; Bex F; Hallez S; Leclere J; Peronneau P; Mami-Chouaib F; Chouaib S
    Gene Ther; 1999 Apr; 6(4):606-15. PubMed ID: 10476220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis.
    Yin X; Wang W; Zhu X; Wang Y; Wu S; Wang Z; Wang L; Du Z; Gao J; Yu J
    Biochem Biophys Res Commun; 2015 Sep; 465(2):239-44. PubMed ID: 26253468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas.
    Rodriguez-Madoz JR; Prieto J; Smerdou C
    Mol Ther; 2005 Jul; 12(1):153-63. PubMed ID: 15963931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade.
    Quetglas JI; Labiano S; Aznar MÁ; Bolaños E; Azpilikueta A; Rodriguez I; Casales E; Sánchez-Paulete AR; Segura V; Smerdou C; Melero I
    Cancer Immunol Res; 2015 May; 3(5):449-54. PubMed ID: 25691326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
    Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
    Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.
    Zhou X; Berglund P; Zhao H; Liljeström P; Jondal M
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):3009-13. PubMed ID: 7708765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses.
    Quetglas JI; Rodriguez-Madoz JR; Bezunartea J; Ruiz-Guillen M; Casales E; Medina-Echeverz J; Prieto J; Berraondo P; Hervas-Stubbs S; Smerdou C
    J Immunol; 2013 Mar; 190(6):2994-3004. PubMed ID: 23401594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12.
    Yamanaka R; Zullo SA; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG
    Neurosurg Focus; 2000 Dec; 9(6):e7. PubMed ID: 16817690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
    Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
    J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2(180-188) peptides.
    Sin JI; Park JB; Lee IH; Park D; Choi YS; Choe J; Celis E
    Cancer Immunol Immunother; 2012 Oct; 61(10):1671-82. PubMed ID: 22382361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.